Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
eNq9mE1z2jAQhu/8Co8PvdnGARJoDZmWJi0zyYSSMO30khH2EkSF5OiDQH59ZUwa0pEnqUA9AZL97lq7evTi5HS1IN4SuMCMdv04rPse0JRlmN51/fHNedD2T3u1ZI6WaOeyk7Aexke+lxIkRNcvZsMJICrCH5cXn0HfD9zv1byETeaQyhfXKYlJ+BWJ2SXKi2u8ZMlw5i1AzljW9XMlN6NeIiTXWfQeGP8lcpRCEm1Hdmfnt83d8SQqxN6gqgTwC0TvjKJArTRTxTlQ2UcS7hhfV+TbsNLGYgSCKZ7CEMnZkLMlziAzhpgiIsAqyPQhuwa+JCCLIEbxaJ4uhJU4mqPVCO4H5qQ/6tm+XMmgHsQn7aNGXI87zcZxxyoU31kqcxX0Q0T5baPZqTdazQhoRNY0R/wRBYwg/QVPArbUH4gGKaIpcMuiDRmXiDgqFxb9lx3nKA6H+1fbIsMiJ2gdzkVuu1SIIz0NXHPB3YMUT3DDNamIXrO/9KkiJPrHrMdbjjjKuMBUnykqK3ByPrJdiD6jElbVFbUjoFxtexGDOJzsI6Nm+g/VhODUlnWaRgqEHI8G1aj7L5T4hASMuTtMfMc0Yw/i8PjZLbej7PMNQY2iOc/i26NO+zhutax310/dWxVn0pniLIdIgwmLfXgzoFO2L2l0u5qlnprVfZ9uLBNLEYEK0xRY0kg36JPHc7YF3G2vcsIo+uXsxrZvving6+vNT6M0zrp/Km6Hahf81136WuLlfi6Sr7fanUbzHVrkH57ceNfSeZeiToy34mb4zKTMxfsomiERCKTXMpxyixPj1Lgeh1gTjefnErv7w+DER5S+qkSzo9Qn5Zn79tra7uTXXMa+znl7/9ahG2NIrmCPOpTQd4bmwdnhaf9sm52lPXzBHHdhNhYXScyoK4elJmZS73W+6LrSc67hcDWd4oqXN5V9mUTli6NeLYmKl0a92m8AwiRE
nNbKsz8m9VrK30EQ